News Story: Full Text
Sponsored By
Medicenna Trial
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Phase I/II trial of a twice-daily regimen of temozolomide and celecoxib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.



Website: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-004202,00.asp

Posted on: 06/08/2004

Phase I/II trial of a twice-daily regimen of temozolomide and celecoxib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.

Meeting: 2004 ASCO Annual Meeting

Category: Central Nervous System Tumors

SubCategory: CNS Tumors



Abstract No: 1549

Author(s): S. Pannullo, S. Hariharan, J. Serventi, R. Hayes, C. Balmaceda, J. Burton; JFK Medical Center, Edison, NJ; NYPH-Weill Cornell, New York, NY; Columbia Presbyterian Hospital, New York, NY; Staten Island University Hospital, Staten Island, NY

Abstract: Background: Combination therapy using agents with different mechanisms of action and non-overlapping toxicity may be a safe and effective strategy in cancer therapy. As seen in Phase I of this trial, BID temozolomide [Temodar (TMZ)] in combination with celecoxib (Celebrex) is a safe treatment regimen for malignant glioma. Phase II of this clinical trial tests the hypothesis that celecoxib combined with a BID schedule of TMZ is a more effective therapy for recurrent/progressive malignant glioma.

Methods: Patients received a loading dose of 200 mg/m2 of TMZ followed by 9 doses of 90 mg/m2 TMZ BID for 5 days of every 28 day cycle. Celecoxib was given to a maximum dose of 480 mg/m2 for 10 days. The regimen was well-tolerated by most patients. Hematologic toxicity was mild and did not recur following TMZ dose reduction.

Results: 36 patients (22 M, 14 F) received 141 cycles of therapy. Interim responses were evaluated after 2 cycles. In the 29 patients evaluable for response, 5/29 (17%) had a partial response (PR), 21/29 (72.5%) had stable disease (SD), and 3/29 (10.5%) had progressive disease, resulting in an overall response rate of 90% at 2 months. One patient had a CR after 7 cycles. One patient had a PR for 13 cycles but developed spinal cord tumor. Average duration of response was 5.2 months (range, 2-13). The 6-month PFS for 23 evaluable patients was 8/23(35%) and 6-month overall survival rate of 19/23(83%).

Conclusions: A regimen of twice-daily TMZ and celecoxib is a safe and potentially effective regimen for the treatment of recurrent high-grade glioma.


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites